肝动脉栓塞术联合射频消融术治疗肝细胞癌的临床应用评价

The clinical efficacy of treatment hepatocellular carcinoma with transcatheter arterial chemoembolization combined radiofrequency ablation

目的比较肝动脉化疗栓塞(TACE)联合射频消融(RFA)治疗肝细胞癌与单纯TACE治疗的临床疗效。方法搜集自2007年1月至2011年1月208例肝细胞癌介入治疗的患者并进行分组,纳入研究范围标准为肝功能child分级A^B级,最大肿块直径(或2~3个病变直径总和)3.0~10.0cm,其中行TACE+RFA患者为治疗组共98例,对照组TACE患者110例。分别从临床症状、影像学表现、甲胎蛋白(AFP)数值、复发率、生存期等方面进行比较分析,评价临床疗效。结果治疗组与对照组在肿瘤坏死程度、肿瘤复发比率、AFP数值变化、生存期方面比较,差异有统计学意义(P<0.05)。结论肝动脉化疗栓塞术联合射频消融术治疗肝细胞癌,临床治疗效果优于单纯肝动脉化疗栓塞术,是治疗肝细胞癌非手术患者的有效方法。

Objective To compare the clinical efficacy of treatment hepatocellular carcinoma with transcatheter arterial chemoembolization（ TACE） combined radiofrequency ablation（ RFA） and TACE alone. Methods collected hospitalized patients from January 2007 to January 2011,208 cases of hepatocellular carcinoma in patients with interventional treatment group,included in the study criteria for the classification of liver function child A ～ B grade,maximum tumor diameter（ or 2 ～ 3 lesions diameter sum）3. 0 ～ 10. 0cm,where the line for the treatment of patients with TACE ＋ RFA group of 98 patients in the control group TACE 110 patients. Respectively,from the comparative analysis of the clinical symptoms,imaging findings,alpha-fetoprotein（ AFP） values,the recurrence rate,survival,etc.,to evaluate the clinical efficacy. Results The difference was statistically significant between the treatment group and the control group in tumor necrosis,tumor recurrence rate,AFP value change,survival aspects（ P 0. 05）. Conclusion The hepatocellular carcinoma clinical outcomes of Hepatic arterial chemoembolization combined with radiofrequency ablation is better than the hepatic artery chemoembolization. This is an effective non-surgical method for the treatment of patients with hepatocellular carcinoma.